Type 1 DiabetesNCT02105324
The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas
A study testing Bionic Pancreas in people with Type 1 Diabetes, run by Massachusetts General Hospital at 1 site in United States.
Trial summary
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers both insulin and glucagon can improve glycemic control vs. usual care for young people with type 1 diabetes ages 6-11 years old in a diabetes camp environment. Read more about this study
- Who is it for?
- Ages 6 to 11 years
- Conditions the study is for
- Type 1 Diabetes
- What is being tested?
- Bionic Pancreas
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 19 participants
- Where
- 1 siteUnited States
- Study dates
- Jun 2014to Aug 2014
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 11 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Age 6-11 years with type 1 diabetes for at least one year
- Diabetes managed using an insulin infusion pump for ≥ three months
- Willing to wear two infusion sets and continuous glucose monitoring (CGM) sensor and change sets frequently (at least one new glucagon infusion set daily)
- Otherwise healthy (mild chronic disease such as asthma will be allowed if well controlled that do not require medications that result in exclusion)
Who cannot join
- Unable to provide informed consent, informed assent or parental consent
- Unable to comply with study procedures
- Current participation in another diabetes-related clinical trial that, in the judgment of the principal investigator, will compromise the results of this study or the safety of the subject
- End stage renal disease on dialysis (hemodialysis or peritoneal dialysis)
- Pregnancy (positive urine human chorionic gonadotropin [HCG])
- History of liver disease that is expected to interfere with the anti-hypoglycemia action of glucagon (e.g. liver failure or cirrhosis). Other liver disease (i.e. active hepatitis, steatosis, active biliary disease, any tumor of the liver, hemochromatosis, glycogen storage disease) may exclude the subject if it causes significant compromise to liver function or may do so in an unpredictable fashion
Show all 18Show fewer
- Personal history of cystic fibrosis, pancreatitis, or other pancreatic disease, including pancreatic tumor or insulinoma
- History of prolonged QT or arrhythmia, congenital heart disease or current known cardiac disease
- Acute illness (other than non-vomiting viral illness) or exacerbation of chronic illness other than type 1 diabetes (T1D) at the time of the study
- Seizure disorder, history of any seizure within the last two years, or ongoing treatment with anticonvulsants
- Untreated or inadequately treated mental illness (indicators would include symptoms such as psychosis, hallucinations, mania, and any psychiatric hospitalization in the last year), or treatment with second generation anti-psychotic medications, which are known to affect glucose regulation.
- Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be susceptible to radio-frequency (RF) interference
- Use of oral (e.g. thiazolidinediones, biguanides, sulfonylureas, glitinides, dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose linked transporter 2 (SGLT-2) inhibitors) anti-diabetic medications
- History of adverse reaction to glucagon (including allergy) besides nausea and vomiting.
- Unwilling or unable to completely avoid acetaminophen during the comparator and bionic pancreas arms of the study
- History of eating disorder such as anorexia, bulimia, or diabulemia or omission of insulin to manipulate weight
- History of intentional, inappropriate administration of insulin leading to severe hypoglycemia requiring treatment
- Any factors that, in the opinion of the principal investigator, would interfere with the safe completion of the study procedures
Trial locations and contacts
1 site in 1 country.
United States1 site
Massachusetts General Hospital
Boston, Massachusetts, 02114
About this study
Official title: The Summer Camp Study 2: Outpatient Automated Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas in a Pediatric Population Ages 6-11 at the Clara Barton Diabetes Camps
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers both insulin and glucagon can improve glycemic control vs. usual care for young people with type 1 diabetes ages 6-11 years old in a diabetes camp environment.
- Conditions
- Type 1 Diabetes
- Being tested
- Bionic Pancreas, Usual Care
- Keywords
- bionic pancreas, artificial pancreas, insulin, glucagon, continuous glucose monitoring (CGM), outpatient, insulin pump, pediatrics, children, camp, summer camp
- Medical subject headings
- Diabetes Mellitus, Type 1, Insulin Resistance, Muscle Cramp
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bionic PancreasDevice
Also called Boston University Bionic Pancreas
Automated blood glucose control via a closed-loop bionic pancreas device.
Usual CareOther
As a comparator control, usual diabetes camp care with the participant's own insulin pump.
| Study group | Role | What they receive |
|---|---|---|
| Bionic Pancreas | Experimental | Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 5 days. Receives: Device: Bionic Pancreas |
| Usual Care | Experimental | Usual Care diabetes management in a diabetes camp environment including a nurse or nursing student assigned to each cabin and review and adjustment of the insulin regimen daily by a physician or nurse practitioner, all participants using the participant's own insulin pump and a continuous glucose monitor if they use one as part of their usual care, for 5 days. Receives: Other: Usual Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Continuous Glucose Monitoring Glucose (CGMG) Values During Days 2 to 5
Glucose reading were taken every 5 minutes by the CGM. The CGM glucose results during Days 2 through 5 were averaged.
Measured: Days 2 to 5 of each period
Percentage of Time Spent With CGMG Concentration < 60 mg/dL During Days 2 to 5
Glucose reading were taken every 5 minutes by the CGM. The percentage of time that the glucose concentration was less than 60 mg/dL [3.3 millimoles/liter (mmol/L)] during Days 2 through 5 was calculated.
Measured: Days 2 to 5 of each period
Secondary outcomes (38)
Mean CGMG Values
Glucose reading were taken every 5 minutes by the CGM. The glucose results for each time frame were averaged.
Measured: Day 1 and Days 1-5 in each period
Percentage of Time With CGMG Concentration by Ranges During Day 1
Glucose readings were taken every 5 minutes by the CGM. The percentage of time that the glucose concentration was less than the following ranges were calculated: < 50 mg/dL(2.8 mmol/L), < 70 mg/dL (3.9 mmol/L), 70-180 mg/dL (3.9 to 10.0 mmol/L), > 180 mg/dL (10.0 mmol/L).
Measured: Day 1 of each period
Percentage of Time With CGMG Concentration by Ranges During Days 1 to 5
Glucose readings were taken every 5 minutes by the CGM. The percentage of time that the glucose concentration was less than the following ranges were calculated: < 50 mg/dl (2.8 mmol/L), < 70 mg/dl (3.9 mmol/L), 70-180 mg/dl (3.9 to 10.0 mmol/L), > 180 mg/dL (10.0 mmol/L).
Measured: Days 1 to 5 of each period
Percentage of Time With CGMG Concentration by Ranges During Days 2 to 5
Glucose readings were taken every 5 minutes by the CGM. The percentage of time that the glucose concentration was less than the following ranges were calculated: < 50 mg/dl (2.8 mmol/L), < 70 mg/dl (3.9 mmol/L), 70-180 mg/dl (3.9 to 10.0 mmol/L), > 180 mg/dL (10.0 mmol/L).
Measured: Days 2 to 5 of each period
Percentage of Participants With Mean CGMG Glucose <154 mg/dL
Glucose reading were taken every 5 minutes by the CGM. The glucose readings were averaged. 154 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 7.0%.
Measured: Day 1, Days 1-5, and Days 2-5 of each period
Percentage of Participants With Mean CGMG Glucose <169 mg/dL
Glucose reading were taken every 5 minutes by the CGM. The glucose readings were averaged. 169 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 7.5%.
Measured: Day 1, Days 1-5, and Days 2-5 of each period
Percentage of Participants With Mean CGMG Glucose <183 mg/dL
Glucose reading were taken every 5 minutes by the CGM. The glucose readings were averaged. 183 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 8.0%.
Measured: Day 1, Days 1-5, and Days 2-5 of each period
Number of CGMG Reported Hypoglycemic Events (< 70 mg/dL, < 60 mg/dL, <50 mg/dL)
A series of hypoglycemic measurements is defined as a single event until there is a break of ≥ 30 minutes between measurements below the defined thresholds of < 70, < 60, and <50 mg/dL.
Measured: Days 1-5
Mean Plasma Glucose Values
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The plasma glucose readings were averaged. The plasma glucose results on Day 1, Days 1 to 5 and Days 2 to 5 were averaged.
Measured: Day 1, Days 1 to 5, and Days 2 to 5 of each period
Percentage of Time With Plasma Glucose Values by Ranges on Day 1
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The percentage of time that the plasma glucose concentration was less than the following ranges were calculated: < 70 mg/dl (3.9 mmol/L), < 60 mg/dL (3.3 mmol/L), < 50 mg/dl (2.8 mmol/L).
Measured: Day 1 of each period
Percentage of Time With Plasma Glucose Values by Ranges on Days 1 to 5
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The percentage of time that the plasma glucose concentration was less than the following ranges were calculated: < 70 mg/dL (3.9 mmol/L), < 60 mg/dL (3.3 mmol/L), < 50 mg/dL (2.8 mmol/L).
Measured: Days 1 to 5 of each period
Percentage of Time With Plasma Glucose Values by Ranges on Days 2 to 5
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The percentage of time that the plasma glucose concentration was less than the following ranges were calculated: < 70 mg/dl (3.9 mmol/L), < 60 mg/dL (3.3 mmol/L), < 50 mg/dl (2.8 mmol/L).
Measured: Days 2 to 5 of each period
Percentage of Participants With Mean Plasma Glucose <154 mg/dL
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The plasma glucose readings were averaged. 154 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 7.0%.
Measured: Day 1, Days 1 to 5, and Days 2 to 5 of each period
Percentage of Participants With Mean Plasma Glucose <169 mg/dL
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The plasma glucose readings were averaged. 169 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 7.5%.
Measured: Day 1, Days 1 to 5, and Days 2 to 5 of each period
Percentage of Participants With Mean Plasma Glucose <183 mg/dL
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). The plasma glucose readings were averaged. 183 mg/dL was the estimated average glucose corresponding to a Hemoglobin A1C of 8.0%.
Measured: Day 1, Days 1 to 5, and Days 2 to 5 of each period
Number of Plasma Glucose Reported Hypoglycemic Events (< 70 mg/dL, < 60 mg/dL, <50 mg/dL)
A series of hypoglycemic measurements is defined as a single event until there is a break of ≥ 30 minutes between measurements below the defined thresholds of < 70, < 60, and <50 mg/dL.
Measured: Days 1-5
Percentage of Days That CGM Data Was Used by Participants as Part of Their Usual Care
The percentage of days during the Usual Care period that participants used CGM data as part of their diabetes management.
Measured: Day 1, Days 1-5, and Days 2-5 of the Usual Care Period
Number of Carbohydrate Interventions for Hypoglycemia When Plasma Glucose <70 mg/dL
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). Participants were given 15 grams (g) of simple carbohydrates if their plasma glucose concentration dropped below 4.4 mmol/L. These simple carbohydrates were counted as interventions for study outcomes if the plasma glucose concentration was less than 3.9 mmol/L. A second intervention of 15 g of carbohydrate was given if a repeat measurement in 15-20 min was less than 3.9 mmol/L. The total number of carbohydrate interventions are reported.
Measured: Day 1, Days 1-5, and Days 2-5 of each period
Grams of Carbohydrate Taken for Hypoglycemia When Plasma Glucose <70 mg/dL
Fingerstick plasma glucose measurements were obtained before meals, at bedtime, at midnight, and at about 3:45 AM (six scheduled measurements). Participants were given 15 grams (g) of simple carbohydrates if their plasma glucose concentration dropped below 4.4 mmol/L. These simple carbohydrates were counted as interventions for study outcomes if the plasma glucose concentration was less than 3.9 mmol/L. A second intervention of 15 g of carbohydrate was given if a repeat measurement in 15-20 min was less than 3.9 mmol/L.
Measured: Day 1, Days 1-5, and Days 2-5 of each period
Insulin Total Daily Dose
Insulin total daily dose is reported in units per kilogram per day (U/kg/day).
Measured: 11 days
Glucagon Total Daily Dose Levels in the Bionic Pancreas Arm
Glucagon dose level is reported in micrograms per kilogram of body mass per day (µg/kg/day).
Measured: Day 1, Days 1-5, and Days 2-5 of each period
Daily Basal Insulin Dose in the Bionic Pancreas Period
The bionic pancreas automatically adapted insulin dosing to each individual's needs. When CGM data were not available (because of sensor failure or during the warm-up time after sensor replacement), the bionic pancreas automatically delivered a dose of basal insulin based on the mean basal dosing it had calculated at that time on previous days. Daily basal insulin dose is reported in units per kilogram (kg) per day (U/kg).
Measured: Day 1 through Day 5
Daily Bolus Insulin Dose in the Bionic Pancreas Period
The first time the bionic pancreas was used in each participant, a partial meal-priming bolus based on the participant's body mass (0.05 units/kg) was delivered. After the first use, the size of the meal-priming bolus was adapted by the bionic pancreas to 75% of the 4-hour prandial insulin used for that meal type and size. Daily bolus insulin dose is reported in units per kilogram (kg) per day (U/kg).
Measured: Day 1 through Day 5
Carbohydrate Intake
Carbohydrate intake included meals, snacks and unscheduled carbohydrates administered when a participant's blood glucose was <80 mg/dl (or for symptoms at any glucose level). Carbohydrate intake per day was averaged and is reported in grams (g) per kilogram (kg) per day (g/kg/day).
Measured: Day 1, Days 1-5 and Days 2-5
Number of Unscheduled Infusion Set Changes
Infusion sets for administering insulin and glucagon were placed under the skin the in the abdomen, buttocks, arms, or legs. Infusion set changes due to pain, infusion set falling out or infusion set failure are reported. Camp policy was to suspect failure of the infusion set whenever ketonemia occurred, so failures may not have actually been set failures, but rather failure to deliver enough insulin.
Measured: Day 1
Number of Unscheduled Infusion Set Changes
Infusion sets for administering insulin and glucagon were placed under the skin the in the abdomen, buttocks, arms, or legs. Infusion set changes due to pain, infusion set falling out or infusion set failure are reported. Camp policy was to suspect failure of the infusion set whenever ketonemia occurred, so failures may not have actually been set failures, but rather failure to deliver enough insulin.
Measured: Days 1-5
Number of Unscheduled Infusion Set Changes
Infusion sets for administering insulin and glucagon were placed under the skin the in the abdomen, buttocks, arms, or legs. Infusion set changes due to pain, infusion set falling out or infusion set failure are reported. Camp policy was to suspect failure of the infusion set whenever ketonemia occurred, so failures may not have actually been set failures, but rather failure to deliver enough insulin.
Measured: Days 2-5
Number of Bionic Pancreas Local Infusion Site Reactions
Local infusion site reactions are defined as pain at the infusion site of the Bionic Pancreas. Itching and redness may have also been present.
Measured: Day 1, Days 1-5 and Days 2-5
Mean Nausea Index Score Using a Visual Analogue Scale (VAS)
Participants rated their nausea using a 0 to 10 centimeter (cm) VAS where 0=least severe nausea to 10=most severe nausea. The average nausea index scores from Day 1 to Day 5 were calculated
Measured: Day 1, Days 1-5, and Days 2-5 in each period
Number of Severe Hypoglycemic Events
A severe hypoglycemic event is an event where the participant is unable to self-treat and requires the assistance of another person.
Measured: Day 1, Days 1-5 and Days 2-5
Percentage of Time Participants Were Not Under Bionic Pancreas Control During the Bionic Pancreas Period
Percentage of time that the Bionic pancreas was not functioning properly due to loss of wireless connectivity.
Measured: 5 days
Percentage of Time Without CGM Monitoring Data
Percentage of time without CGM monitoring data is the time when the participant's CGM device lost its CGM signal.
Measured: 5 days
Change From Baseline in Body Weight
The change in body weight collected at Day 5 of each period relative to Baseline. A negative change from Baseline indicates a reduction in body weight and a positive change from Baseline indicates an increase in body weight.
Measured: 5 days
Reliability Index
Reliability index was calculated as the percentage of time values were actually recorded by CGM.
Measured: Day 1, Days 1-5, and Days 2-5 in each period
List of Technical Faults Associated With the Bionic Pancreas Including Cause and Resolution
Measured: 5 days
Number of Unscheduled CGM Sensor Changes
The number of time a CGM sensor was replaced due to falling out or failing to report a glucose value.
Measured: 5 days
Percentage of Participants Using a Glucagon-Like Peptide-1 (GLP-1) Agonist During the Usual Care Period
The percentage of participants who used a GLP-1 agonist to manage their diabetes during the Usual Care period.
Measured: 5 days
Percentage of Participants Using Pramlintide During the Usual Care Period
The percentage of participants who used pramlintide to manage their diabetes during the Usual Care period.
Measured: 5 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Apr 2014 (estimated)
- Study startJun 2014
- Primary completionAug 2014
- Study completionAug 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Type 1 DiabetesStudies of the same condition, open and under way.
- More trials run by Massachusetts General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 19 participants (actual)
Sponsor and investigators
- Lead sponsor
- Massachusetts General Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Boston University
- Responsible party
- Principal investigator, Steven J. Russell, MD, PhD, Massachusetts General Hospital
- Investigators
- Steven J Russell, MD PhD, Principal investigator, Massachusetts General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02105324
- Sponsor's protocol ID
- 2014P000630
- Status last verified
- Oct 2017
- First submitted
- 2 Apr 2014
- Last updated
- 20 Oct 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Russell SJ, Hillard MA, Balliro C, Magyar KL, Selagamsetty R, Sinha M, Grennan K, Mondesir D, Ekhlaspour L, Zheng H, Damiano ER, El-Khatib FH. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol. 2016 Mar;4(3):233-243. doi: 10.1016/S2213-8587(15)00489-1. Epub 2016 Feb 3.
PubMed 26850709
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Summer Camp Study 2: Outpatient Automated Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas in a Pediatric Population Ages 6-11 at the Clara Barton Diabetes Camps
- ClinicalTrials.gov ID
- NCT02105324
- Acronym / sponsor ID
- 2014P000630
- Conditions
- Type 1 Diabetes
- Keywords
- bionic pancreas, artificial pancreas, insulin, glucagon, continuous glucose monitoring (CGM), outpatient, insulin pump, pediatrics
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 19 participants (actual)
- Lead sponsor
- Massachusetts General HospitalUniversity, hospital or other
- Collaborators
- Boston University
- Study start
- Jun 2014
- Primary completion
- Aug 2014 (actual)
- Study completion
- Aug 2014 (actual)
- First posted
- 7 Apr 2014 (estimated)
- Results
- Posted 20 Oct 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers both insulin and glucagon can improve glycemic control vs. usual care for young people with type 1 diabetes ages 6-11 years old in a diabetes camp environment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Bionic Pancreas | Experimental | Device: Bionic PancreasBionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 5 days. |
| Usual Care | Experimental | Other: Usual CareUsual Care diabetes management in a diabetes camp environment including a nurse or nursing student assigned to each cabin and review and adjustment of the insulin regimen daily by a physician or nurse practitioner, all participants using the participant's own insulin pump and a continuous glucose monitor if they use one as part of their usual care, for 5 days. |
Who may qualify
- Ages
- 6 to 11 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Age 6-11 years with type 1 diabetes for at least one year
- Diabetes managed using an insulin infusion pump for ≥ three months
- Willing to wear two infusion sets and continuous glucose monitoring (CGM) sensor and change sets frequently (at least one new glucagon infusion set daily)
- Otherwise healthy (mild chronic disease such as asthma will be allowed if well controlled that do not require medications that result in exclusion)
Key exclusion criteria (18 listed)
- Unable to provide informed consent, informed assent or parental consent
- Unable to comply with study procedures
- Current participation in another diabetes-related clinical trial that, in the judgment of the principal investigator, will compromise the results of this study or the safety of the subject
- End stage renal disease on dialysis (hemodialysis or peritoneal dialysis)
- Pregnancy (positive urine human chorionic gonadotropin [HCG])
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bionic PancreasAlso: Boston University Bionic PancreasAutomated blood glucose control via a closed-loop bionic pancreas device. | Device | Bionic Pancreas |
| Usual CareAs a comparator control, usual diabetes camp care with the participant's own insulin pump. | Other | Usual Care |
Primary outcome
Mean Continuous Glucose Monitoring Glucose (CGMG) Values During Days 2 to 5
Time frame: Days 2 to 5 of each period
Glucose reading were taken every 5 minutes by the CGM. The CGM glucose results during Days 2 through 5 were averaged.
Percentage of Time Spent With CGMG Concentration < 60 mg/dL During Days 2 to 5
Time frame: Days 2 to 5 of each period
Glucose reading were taken every 5 minutes by the CGM. The percentage of time that the glucose concentration was less than 60 mg/dL [3.3 millimoles/liter (mmol/L)] during Days 2 through 5 was calculated.
38 secondary outcomes
Mean CGMG Values
Time frame: Day 1 and Days 1-5 in each period
Percentage of Time With CGMG Concentration by Ranges During Day 1
Time frame: Day 1 of each period
Percentage of Time With CGMG Concentration by Ranges During Days 1 to 5
Time frame: Days 1 to 5 of each period
Percentage of Time With CGMG Concentration by Ranges During Days 2 to 5
Time frame: Days 2 to 5 of each period
Percentage of Participants With Mean CGMG Glucose <154 mg/dL
Time frame: Day 1, Days 1-5, and Days 2-5 of each period
Percentage of Participants With Mean CGMG Glucose <169 mg/dL
Time frame: Day 1, Days 1-5, and Days 2-5 of each period
Percentage of Participants With Mean CGMG Glucose <183 mg/dL
Time frame: Day 1, Days 1-5, and Days 2-5 of each period
Number of CGMG Reported Hypoglycemic Events (< 70 mg/dL, < 60 mg/dL, <50 mg/dL)
Time frame: Days 1-5
Mean Plasma Glucose Values
Time frame: Day 1, Days 1 to 5, and Days 2 to 5 of each period
Percentage of Time With Plasma Glucose Values by Ranges on Day 1
Time frame: Day 1 of each period
Percentage of Time With Plasma Glucose Values by Ranges on Days 1 to 5
Time frame: Days 1 to 5 of each period
Percentage of Time With Plasma Glucose Values by Ranges on Days 2 to 5
Time frame: Days 2 to 5 of each period
Percentage of Participants With Mean Plasma Glucose <154 mg/dL
Time frame: Day 1, Days 1 to 5, and Days 2 to 5 of each period
Percentage of Participants With Mean Plasma Glucose <169 mg/dL
Time frame: Day 1, Days 1 to 5, and Days 2 to 5 of each period
Percentage of Participants With Mean Plasma Glucose <183 mg/dL
Time frame: Day 1, Days 1 to 5, and Days 2 to 5 of each period
Number of Plasma Glucose Reported Hypoglycemic Events (< 70 mg/dL, < 60 mg/dL, <50 mg/dL)
Time frame: Days 1-5
Percentage of Days That CGM Data Was Used by Participants as Part of Their Usual Care
Time frame: Day 1, Days 1-5, and Days 2-5 of the Usual Care Period
Number of Carbohydrate Interventions for Hypoglycemia When Plasma Glucose <70 mg/dL
Time frame: Day 1, Days 1-5, and Days 2-5 of each period
Grams of Carbohydrate Taken for Hypoglycemia When Plasma Glucose <70 mg/dL
Time frame: Day 1, Days 1-5, and Days 2-5 of each period
Insulin Total Daily Dose
Time frame: 11 days
Glucagon Total Daily Dose Levels in the Bionic Pancreas Arm
Time frame: Day 1, Days 1-5, and Days 2-5 of each period
Daily Basal Insulin Dose in the Bionic Pancreas Period
Time frame: Day 1 through Day 5
Daily Bolus Insulin Dose in the Bionic Pancreas Period
Time frame: Day 1 through Day 5
Carbohydrate Intake
Time frame: Day 1, Days 1-5 and Days 2-5
Number of Unscheduled Infusion Set Changes
Time frame: Day 1
Number of Unscheduled Infusion Set Changes
Time frame: Days 1-5
Number of Unscheduled Infusion Set Changes
Time frame: Days 2-5
Number of Bionic Pancreas Local Infusion Site Reactions
Time frame: Day 1, Days 1-5 and Days 2-5
Mean Nausea Index Score Using a Visual Analogue Scale (VAS)
Time frame: Day 1, Days 1-5, and Days 2-5 in each period
Number of Severe Hypoglycemic Events
Time frame: Day 1, Days 1-5 and Days 2-5
Percentage of Time Participants Were Not Under Bionic Pancreas Control During the Bionic Pancreas Period
Time frame: 5 days
Percentage of Time Without CGM Monitoring Data
Time frame: 5 days
Change From Baseline in Body Weight
Time frame: 5 days
Reliability Index
Time frame: Day 1, Days 1-5, and Days 2-5 in each period
List of Technical Faults Associated With the Bionic Pancreas Including Cause and Resolution
Time frame: 5 days
Number of Unscheduled CGM Sensor Changes
Time frame: 5 days
Percentage of Participants Using a Glucagon-Like Peptide-1 (GLP-1) Agonist During the Usual Care Period
Time frame: 5 days
Percentage of Participants Using Pramlintide During the Usual Care Period
Time frame: 5 days
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 26850709Russell SJ, Hillard MA, Balliro C, Magyar KL, Selagamsetty R, Sinha M, Grennan K, Mondesir D, Ekhlaspour L, Zheng H, Damiano ER, El-Khatib FH. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol. 2016 Mar;4(3):233-243. doi: 10.1016/S2213-8587(15)00489-1. Epub 2016 Feb 3.
- Information about this and related studiesLink provided by the sponsor.
Related trials for Type 1 Diabetes
Active, not recruitingPhase 3
Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes
Type 1 Diabetes
RecruitingObservational study
Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy
Type 1 Diabetes
Active, not recruitingPhase 1/2
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Obesity
RecruitingPhase 3
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
Obesity or Overweight
Not yet recruitingPhase 1/2
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
Sarcoma, Osteoid Sarcoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Steven J Russell, MD PhD principal investigator
Massachusetts General Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Bionic Pancreas in people with Type 1 Diabetes, run by Massachusetts General Hospital at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Oct 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 20 Oct 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Continuous Glucose Monitoring Glucose (CGMG) Values During Days 2 to 5 (time frame: Days 2 to 5 of each period). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02105324, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2017.